CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Germany

Pharmaceutical market in Germany is expected to reach approximately $65.6 billion by 2020 at 3.3% Compound Annual Growth Rate (CAGR). Valued at $51.5 in 2012, with the population of 82 million and growing, the progression of value is expected to be significant in the pharmaceutical market. The Medical device market was worth approximately $22.1 billion in 2012; it is expected to reach approximately $32.6 billion by 2020 at CAGR 5%, reveals new report.

This report provides insights into the demographic, reimbursement and regulatory landscape, healthcare infrastructure and key trends in the healthcare market, along with insights into the trends and segmentation of the pharmaceutical and medical devices markets. This report is built to provide essential source of information by using informed data, information source from proprietary databases, secondary research and in-house analysis.

Spanning over 323 pages, 115 tables and 105 figures, “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Germany”, report helps in enhancing decision making capabilities following carefully developing business strategies by understanding German Healthcare industry, to formulate effective sales and marketing strategies by understanding performance of various competitors, and capitalizing on the opportunities and challenges in the German healthcare market.

In addition to the insightful review of the reimbursement and regulatory landscape, the report also covers profiles and SWOT analyses of the major players in the pharmaceutical market, namely Pfizer, Abbott, F. Hoffmann-La Roche, Novartis, and GlaxoSmithKline (GSK); and medical device market, namely Siemens Healthcare, F. Hoffmann-La Roche, Abbott, B. Braun Melsungen and Medtronic.